Intercept is a biopharmaceutical company that develops and commercializes novel therapeutics to treat non-viral liver diseases.
Business Model:
Revenue: $384.9M
Employees: 201-500
Address: 10 Hudson Yards
City: New York
State: NY
Zip: 10001
Country: US
Intercept is a biopharmaceutical company that develops and commercializes novel therapeutics to treat non-viral liver diseases.
Contact Phone:
+16467471000
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
10/11/2012
Ticker Symbol:
ICPT
IPO Price:
$15/share
Amount Raised:
$75M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2016 | Convertible Note | $44.8M | 8/2012 | Series C | 2 | $30M |
Aisling Capital OrbiMed OrbiMed Aisling Capital OrbiMed OrbiMed |
1/2010 | Series B | 1 | $25M |
Genextra Genextra Genextra Genextra |
7/2008 | Series A | 1 | $25M |
Genextra Genextra Genextra Genextra |
5/2006 | Venture Round | 3 | $41M |
Jafco Life Science Genextra Balyasny Asset Management Genextra Jafco Life Science Genextra Balyasny Asset Management Genextra |
10/2012 | IPO | $75M |
|
6/2016 | Debt | $400M | 4/2015 | Post-IPO Equity | $338.4M | 6/2013 | Post-IPO Equity | $61.7M | 5/2005 | Debt Financing | 1 | $1.3M |
Rodman &a; Renshaw Rodman &a; Renshaw Rodman &a; Renshaw Rodman &a; Renshaw |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|